Please Wait.....
Report
Oral Proteins & Peptides Market by Molecule (Semaglutide, Linaclotide, Calcitonin), Drug Class (GLP-1 Receptor Agonist, GEP, CGRP), Therapeutic Area (Diabetes, Gastroenterology, Genetic Disorder), Formulation (Tablet, Capsule) - Global Forecast to 2030
Market Report I 2025-04-24 I 326 Pages I MarketsandMarkets
The global market for oral proteins and peptides is projected to reach USD 24.00 billion by 2030 from USD 8.85 billion in 2025, at a CAGR of 22.1% during the forecast period from 2025 to 2030.
The increase in demand for oral peptides, particularly for the treatment of chronic diseases such as diabetes and central nervous system (CNS) disorders, is a major driver of growth in this market. Additionally, rising investments in research and development by key players are leading to the creation and launch of innovative oral peptides. Continuous advancements in drug delivery technologies are also contributing to market expansion.
However, the market faces challenges, including high development costs and obstacles related to formulation and stability, which hinder growth.
"The semaglutide molecule segment accounted for the largest share of the market, by molecule, in 2024."
In 2024, the semaglutide segment held the largest share of the global oral proteins and peptides market. Semaglutide is an analog of glucagon-like peptide-1 (GLP-1), a hormone that plays a key role in regulating blood sugar levels and appetite. It is used to manage type 2 diabetes and obesity. Semaglutide functions by enhancing insulin secretion in response to elevated blood glucose levels, reducing glucagon release (which normally raises blood sugar), and promoting a feeling of fullness after eating, thereby helping to reduce food intake.
Oral semaglutide, marketed as RYBELSUS, is the first oral GLP-1 receptor agonist approved by the US FDA for the treatment of type 2 diabetes. As a class, GLP-1 receptor agonists are widely utilized and recommended for managing type 2 diabetes.
"The US will continue to dominate the oral proteins and peptides market during the forecast period."
The US is the largest biopharmaceutical market in the world and a leader in biopharmaceutical research and investments. This growth is driven by several factors, including the increasing patient population suffering from infectious diseases, the rising importance of biopharmaceuticals, and the need for safe, high-quality products in the healthcare sector. There has been a significant increase in investments and funding for biomedical research from government agencies as well as pharmaceutical and biotechnology companies.
Furthermore, the early adoption of emerging technologies and alternative therapies and the widespread availability of oral proteins and peptides in the region support market expansion. The strong presence of several key market players, including Novo Nordisk A/S (Denmark), AbbVie, Inc. (US), and Pfizer Inc. (US), is another crucial factor contributing to this growth.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side (70%) and Demand Side (30%)
- By Designation: Managers (45%), CXOs & Directors (30%), and Executives (25%)
- By Region: North America (40%), Europe (25%), Asia Pacific (25%), Latin America (5%), and Middle East & Africa (5%)
List of Key Companies Profiled in the Report:
Novo Nordisk A/S (Denmark), AbbVie Inc. (US), Pfizer Inc. (US), Acadia Pharmaceuticals Inc. (US), Aurinia Pharmaceuticals Inc. (Canada), Bausch Health Companies Inc. (Canada), CHIESI Farmaceutici S.p.A. (Italy), EnteraBio Ltd. (Israel), Merck & Co., Inc. (US), Johnson & Johnson Services, Inc. (US), R-Pharm JSC (Russia), Proxima Concepts (US), and SWK Holdings Corporation (US)
Research Coverage:
This research report categorizes the oral proteins and peptides market by molecule (trofinetide, semaglutide, linaclotide, voclosporin, plecanatide, calcitonin, and other drugs), drug class (analog of glycine-proline-glutamate (GPE), glucagon-like peptide-1 (GLP-1) receptor agonists, guanylate cyclase-C agonists, calcineurin-inhibitor immunosuppressants, calcitonin gene-related peptide (CGRP) receptor antagonists, and other drugs), therapeutic area (genetic disorders, diabetes, nephrology, gastroenterology, CNS disorders, obesity & overweight, and other therapeutic areas), formulation (tablets, capsules, and oral solutions), end user (home care settings, long-term care facilities, and hospitals & specialty clinics), and region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the oral proteins and peptides market. A comprehensive analysis of key industry players has been conducted to provide insights into their business overview, products, solutions, strategies, collaborations, partnerships, agreements, new launches, acquisitions, and recent developments associated with the oral proteins and peptides market.
Key Benefits of Buying the Report:
The report will help market leaders and new entrants by providing the closest approximations of the revenue numbers for the oral proteins and peptides market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their businesses and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
- Analysis of key drivers (rising prevalence of chronic diseases such as diabetes, gastroenterology diseases, and kidney diseases; advancements in drug delivery technologies; patient preference and compliance for oral route of drug administration; and increasing adoption of inorganic growth strategies such as collaborations and agreements), restraints (high cost associated with drug development, contraindication of oral proteins and peptides, and stringent regulatory approval process), opportunities (robust clinical trial pipeline for oral proteins and peptides and growing demand for non-invasive and patient-friendly treatment options), and Challenges (hurdles in formulation and stability and availability of alternative therapies) influencing the growth of the market.
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the oral proteins and peptides market.
- Market Development: Comprehensive information about lucrative markets; the report analyzes the market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the oral proteins and peptides market.
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players. A detailed analysis of the key industry players has been done to provide insights into their key strategies, product launches/approvals, pipeline analysis, acquisitions, partnerships, agreements, collaborations, other recent developments, investment and funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the oral proteins and peptides market.
1 INTRODUCTION 32
1.1 STUDY OBJECTIVES 32
1.2 MARKET DEFINITION 32
1.3 MARKET SCOPE 33
1.3.1 MARKETS AND REGIONS COVERED 33
1.3.2 INCLUSIONS & EXCLUSIONS 34
1.3.3 YEARS CONSIDERED 34
1.3.4 CURRENCY CONSIDERED 35
1.4 STAKEHOLDERS 35
1.5 SUMMARY OF CHANGES 35
2 RESEARCH METHODOLOGY 36
2.1 RESEARCH DATA 36
2.1.1 RESEARCH DESIGN 36
2.1.2 SECONDARY DATA 37
2.1.3 PRIMARY DATA 37
2.2 MARKET SIZE ESTIMATION 39
2.2.1 INSIGHTS FROM PRIMARIES 41
2.2.2 MARKET SIZE ASSESSMENT AT SEGMENT LEVEL 41
2.3 MARKET GROWTH FORECAST 42
2.4 MARKET BREAKDOWN & DATA TRIANGULATION 44
2.5 STUDY ASSUMPTIONS 45
2.6 RESEARCH LIMITATIONS 45
2.7 RISK ANALYSIS 45
3 EXECUTIVE SUMMARY 46
4 PREMIUM INSIGHTS 50
4.1 ORAL PROTEINS & PEPTIDES MARKET OVERVIEW 50
4.2 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET SHARE, BY FORMULATION AND COUNTRY (2024) 51
4.3 ORAL PROTEINS & PEPTIDES MARKET SHARE, BY THERAPEUTIC AREA, 2024 51
4.4 ORAL PROTEINS & PEPTIDES MARKET SHARE, BY END USER, 2025 VS. 2030 52
4.5 ORAL PROTEINS & PEPTIDES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 52
5 MARKET OVERVIEW 53
5.1 INTRODUCTION 53
5.2 MARKET DYNAMICS 53
5.2.1 DRIVERS 54
5.2.1.1 Increasing burden of chronic diseases 54
5.2.1.2 Advancements in drug delivery technologies 55
5.2.1.3 Higher patient compliance and preference for oral route 55
5.2.1.4 Expanding therapeutic applications of oral proteins & peptides 55
5.2.2 RESTRAINTS 56
5.2.2.1 High cost of drug development 56
5.2.2.2 Contraindication of oral proteins & peptides 56
5.2.2.3 Stringent regulatory approval process 56
5.2.3 OPPORTUNITIES 57
5.2.3.1 Robust clinical trial pipeline for oral proteins & peptides 57
5.2.3.2 Growing demand for personalized medicine 57
5.2.4 CHALLENGES 58
5.2.4.1 Hurdles in formulation and stability 58
5.2.4.2 Availability of alternative therapies 58
5.3 ECOSYSTEM ANALYSIS 59
5.3.1 ROLE OF RAW MATERIAL VENDORS 60
5.3.2 ROLE OF PRODUCT PROVIDERS 60
5.3.3 ROLE OF END USERS 60
5.3.4 ROLE OF REGULATORY AUTHORITIES 61
5.4 VALUE CHAIN ANALYSIS 61
5.5 SUPPLY CHAIN ANALYSIS 63
5.6 PORTER'S FIVE FORCES ANALYSIS 64
5.6.1 THREAT OF NEW ENTRANTS 65
5.6.2 THREAT OF SUBSTITUTES 65
5.6.3 BARGAINING POWER OF SUPPLIERS 66
5.6.4 BARGAINING POWER OF BUYERS 66
5.6.5 INTENSITY OF COMPETITIVE RIVALRY 66
5.7 KEY STAKEHOLDERS & BUYING CRITERIA 66
5.7.1 KEY STAKEHOLDERS 66
5.7.2 BUYING CRITERIA 67
5.8 PRICING ANALYSIS 69
5.8.1 AVERAGE SELLING PRICE, BY KEY PLAYER 69
5.8.2 AVERAGE SELLING PRICE, BY COUNTRY & REGION 70
5.9 REGULATORY LANDSCAPE 71
5.9.1 REGULATORY SCENARIO 71
5.9.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 72
5.10 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES 75
5.11 TECHNOLOGY ANALYSIS 75
5.11.1 KEY TECHNOLOGIES 75
5.11.1.1 Transient permeation enhancers 75
5.11.1.2 Gastrointestinal permeation enhancement technology 75
5.11.1.3 Oral sCT (OSTORA) technology 76
5.11.2 COMPLEMENTARY TECHNOLOGIES 76
5.11.2.1 Peptelligence 76
5.11.2.2 ThioMatrix 76
5.11.2.3 Transferrin-based recombinant fusion proteins 77
5.11.3 ADJACENT TECHNOLOGIES 77
5.11.3.1 Oramed and Orasome 77
5.11.3.2 Q-sphera 77
5.11.3.3 Nanoinclusion 77
5.11.3.4 Oleotec and Soctec 78
5.12 PIPELINE ANALYSIS 78
5.13 PATENT ANALYSIS 79
5.13.1 METHODOLOGY 79
5.13.2 PATENTS APPLIED AND GRANTED, 2014-2025 79
5.14 REIMBURSEMENT SCENARIO 82
5.15 KEY CONFERENCES & EVENTS, 2025-2026 82
5.16 INVESTMENT & FUNDING SCENARIO 83
5.17 IMPACT OF AI ON ORAL PROTEINS & PEPTIDES MARKET 85
5.18 IMPACT OF 2025 US TARIFFS-ORAL PROTEINS & PEPTIDES MARKET 86
5.18.1 INTRODUCTION 86
5.18.2 KEY TARIFF RATES 86
5.18.3 PRICE IMPACT ANALYSIS 87
5.18.4 IMPACT ON COUNTRIES/REGIONS 87
5.18.4.1 US 87
5.18.4.2 Europe 87
5.18.4.3 Asia Pacific 88
5.18.5 IMPACT ON MANUFACTURING INDUSTRIES 88
5.18.6 RECOMMENDATIONS FOR MANUFACTURERS 88
6 ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE 90
6.1 INTRODUCTION 91
6.2 SEMAGLUTIDE 91
6.2.1 INCREASED PATIENT COMPLIANCE TO BOOST MARKET GROWTH 91
6.3 CALCITONIN 94
6.3.1 NEED FOR EFFECTIVE ANTI-MIGRAINE DRUGS TO SUPPORT ADOPTION 94
6.4 LINACLOTIDE 97
6.4.1 RISING PREVALENCE OF GASTRIC DISORDERS TO SUPPORT GROWTH 97
6.5 TROFINETIDE 99
6.5.1 FDA APPROVAL TO DRIVE MARKET 99
?
6.6 VOCLOSPORIN 102
6.6.1 INCREASING REGULATORY APPROVALS TO DRIVE PATIENT ACCESS AND ADOPTION 102
6.7 PLECANATIDE 104
6.7.1 INCREASED PATIENT CONVENIENCE TO SUPPORT GROWTH 104
6.8 OTHER MOLECULES 107
7 ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS 110
7.1 INTRODUCTION 111
7.2 GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS 111
7.2.1 INCREASING ADOPTION TO SUPPORT GROWTH 111
7.3 CALCITONIN GENE-RELATED PEPTIDE RECEPTOR ANTAGONISTS 114
7.3.1 INCREASING PREVALENCE OF MIGRAINE TO DRIVE ADOPTION 114
7.4 GUANYLATE CYCLASE-C AGONISTS 117
7.4.1 RISING PREVALENCE OF IBS AND CIC TO DRIVE MARKET 117
7.5 GLYCINE-PROLINE-GLUTAMATE 119
7.5.1 FOCUS ON DEVELOPING GPE-CLASS DRUGS TO SUPPORT GROWTH 119
7.6 CALCINEURIN-INHIBITOR IMMUNOSUPPRESSANTS 122
7.6.1 INCREASING NUMBER OF ORGAN TRANSPLANTS TO PROMOTE GROWTH 122
7.7 OTHER DRUG CLASSES 124
8 ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION 127
8.1 INTRODUCTION 128
8.2 TABLETS 128
8.2.1 HIGH ADOPTION AND EASE OF ADMINISTRATION TO SUPPORT GROWTH 128
8.3 CAPSULES 131
8.3.1 RISING DEMAND FOR ORAL BIOLOGICS AND INCREASED PATIENT COMPLIANCE TO DRIVE MARKET 131
8.4 ORAL SOLUTIONS 134
8.4.1 GROWING FOCUS ON IMPROVING BIOAVAILABILITY AND PATIENT CONVENIENCE TO SUPPORT MARKET GROWTH 134
9 ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA 137
9.1 INTRODUCTION 138
9.2 DIABETES 138
9.2.1 HIGH EFFICACY TO SUPPORT END-USER ADOPTION 138
9.3 CNS DISORDERS 142
9.3.1 GROWING BURDEN OF NEUROLOGICAL DISORDERS TO PROPEL MARKET 142
9.4 GASTROENTEROLOGY 145
9.4.1 RISING PREVALENCE OF GASTROINTESTINAL DISORDERS TO SUPPORT SEGMENT GROWTH 145
9.5 GENETIC DISORDERS 148
9.5.1 GROWING PREVALENCE OF GENETIC DISORDERS TO SUPPORT GROWTH 148
9.6 NEPHROLOGY 151
9.6.1 RISING PREVALENCE OF KIDNEY DISORDERS IN GERIATRIC POPULATION TO PROPEL MARKET 151
9.7 OBESITY & OVERWEIGHT 153
9.7.1 RISING INCIDENCE OF OBESITY TO PROPEL MARKET GROWTH 153
9.8 OTHER THERAPEUTIC AREAS 156
10 ORAL PROTEINS & PEPTIDES MARKET, BY END USER 159
10.1 INTRODUCTION 160
10.2 HOME CARE SETTINGS 160
10.2.1 RISING NUMBER OF TELEHEALTH COMPANIES AND CONVENIENCE OF HOME CARE TO SUPPORT MARKET GROWTH 160
10.3 LONG-TERM CARE FACILITIES 163
10.3.1 RISING GERIATRIC POPULATION AND PREVALENCE OF CHRONIC DISEASES TO SUPPORT GROWTH 163
10.4 HOSPITALS & SPECIALTY CLINICS 166
10.4.1 ADOPTION OF ORAL PEPTIDES FOR VARIED INDICATIONS TO DRIVE MARKET 166
11 ORAL PROTEINS & PEPTIDES MARKET, BY REGION 170
11.1 INTRODUCTION 171
11.2 NORTH AMERICA 171
11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 172
11.2.2 US 176
11.2.2.1 US to hold large shares in North American and global markets 176
11.2.3 CANADA 178
11.2.3.1 Increasing prevalence of obesity and heart failure to
support market growth 178
11.3 EUROPE 180
11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 181
11.3.2 GERMANY 185
11.3.2.1 Germany to hold largest share of European market 185
11.3.3 UK 188
11.3.3.1 Strong focus on advancement of life sciences to support market growth 188
11.3.4 FRANCE 190
11.3.4.1 Growing prevalence of diabetes and government initiatives to boost market growth 190
11.3.5 ITALY 193
11.3.5.1 Presence of major pharmaceutical and biotechnology companies to drive market 193
11.3.6 SPAIN 195
11.3.6.1 Initiatives associated with GLP-1 drugs to drive market 195
11.3.7 NETHERLANDS 198
11.3.7.1 Rising awareness and focus on pharmaceutical R&D to support market growth 198
11.3.8 REST OF EUROPE 200
11.4 ASIA PACIFIC 202
11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 203
11.4.2 CHINA 207
11.4.2.1 Increasing R&D expenditure to drive market 207
11.4.3 JAPAN 209
11.4.3.1 Increasing prevalence of diabetes to drive market 209
11.4.4 INDIA 212
11.4.4.1 Strong initiatives to develop cost-effective and patient-friendly medications to aid market growth 212
11.4.5 AUSTRALIA 214
11.4.5.1 Rising access to GLP-1 drugs and government support to drive market 214
11.4.6 SOUTH KOREA 217
11.4.6.1 Growing focus on development of innovative treatment solutions to propel market growth 217
11.4.7 REST OF ASIA PACIFIC 219
11.5 LATIN AMERICA 222
11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 222
11.5.2 BRAZIL 225
11.5.2.1 Brazil to hold largest market share in Latin America 225
11.5.3 MEXICO 228
11.5.3.1 Growing diabetes and obesity cases to drive market 228
11.5.4 REST OF LATIN AMERICA 230
11.6 MIDDLE EAST 233
11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST 233
11.6.2 GCC COUNTRIES 236
11.6.2.1 Saudi Arabia 239
11.6.2.1.1 Growing availability of GLP-1 drugs to support market growth 239
11.6.2.2 UAE 241
11.6.2.2.1 Regulatory approvals for GLP-1 drugs to propel market 241
11.6.2.3 Rest of GCC countries 244
11.6.3 REST OF MIDDLE EAST 246
11.7 AFRICA 248
11.7.1 LARGE AND GROWING PATIENT POPULATION AND FAVORABLE HEALTHCARE REFORMS TO DRIVE MARKET 248
11.7.2 MACROECONOMIC OUTLOOK FOR AFRICA 248
?
12 COMPETITIVE LANDSCAPE 252
12.1 OVERVIEW 252
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 252
12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN ORAL PROTEINS & PEPTIDES MARKET 252
12.3 REVENUE ANALYSIS, 2022-2024 253
12.4 MARKET SHARE ANALYSIS, 2024 254
12.5 COMPANY EVALUATION MATRIX 256
12.5.1 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 256
12.5.1.1 Stars 256
12.5.1.2 Emerging leaders 256
12.5.1.3 Pervasive players 257
12.5.1.4 Participants 257
12.5.2 COMPANY EVALUATION MATRIX: PLAYERS WITH PRODUCTS IN PIPELINE, 2024 258
12.5.2.1 Stars 258
12.5.2.2 Emerging leaders 258
12.5.2.3 Pervasive players 258
12.5.2.4 Participants 258
12.5.3 COMPANY FOOTPRINT: KEY PLAYERS, 2024 260
12.5.3.1 Company footprint 260
12.5.3.2 Region footprint 262
12.5.3.3 Molecule footprint 263
12.5.3.4 Formulation footprint 264
12.5.3.5 Therapeutic area footprint 264
12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 266
12.6.1 PROGRESSIVE COMPANIES 266
12.6.2 RESPONSIVE COMPANIES 266
12.6.3 DYNAMIC COMPANIES 266
12.6.4 STARTING BLOCKS 266
12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 268
12.6.5.1 Detailed list of key startups/SMEs 268
12.6.5.2 Competitive benchmarking of key startups/SMEs 269
12.7 VALUATION & FINANCIAL METRICS 270
12.7.1 FINANCIAL METRICS 270
12.7.2 COMPANY VALUATION 270
12.8 BRAND/PRODUCT COMPARISON 271
12.9 COMPETITIVE SCENARIO 271
12.9.1 PRODUCT APPROVALS 271
12.9.2 DEALS 273
12.9.3 EXPANSIONS 274
12.9.4 OTHER DEVELOPMENTS 275
13 COMPANY PROFILES 276
13.1 INTRODUCTION 276
13.2 KEY PLAYERS 276
13.2.1 NOVO NORDISK A/S 276
13.2.1.1 Business overview 276
13.2.1.2 Products offered 277
13.2.1.3 Recent developments 278
13.2.1.3.1 Product launches & approvals 278
13.2.1.3.2 Deals 278
13.2.1.3.3 Expansions 279
13.2.1.3.4 Other developments 280
13.2.1.4 MnM view 280
13.2.1.4.1 Right to win 280
13.2.1.4.2 Strategic choices 280
13.2.1.4.3 Weaknesses & competitive threats 280
13.2.2 ABBVIE INC. 281
13.2.2.1 Business overview 281
13.2.2.2 Products offered 282
13.2.2.3 Recent developments 283
13.2.2.3.1 Product approvals 283
13.2.2.3.2 Deals 283
13.2.2.4 MnM view 284
13.2.2.4.1 Right to win 284
13.2.2.4.2 Strategic choices 284
13.2.2.4.3 Weaknesses & competitive threats 284
13.2.3 PFIZER INC. 285
13.2.3.1 Business overview 285
13.2.3.2 Product pipeline 286
13.2.3.3 Recent developments 287
13.2.3.3.1 Product approvals 287
13.2.3.3.2 Deals 287
13.2.3.3.3 Other developments 287
13.2.3.4 MnM view 288
13.2.3.4.1 Right to win 288
13.2.3.4.2 Strategic choices 288
13.2.3.4.3 Weaknesses & competitive threats 288
13.2.4 BAUSCH HEALTH COMPANIES INC. 289
13.2.4.1 Business overview 289
13.2.4.2 Products offered 290
13.2.4.3 Recent developments 291
13.2.4.3.1 Product approvals 291
?
13.2.5 CHIESI FARMACEUTICI S.P.A. 292
13.2.5.1 Business overview 292
13.2.5.2 Products offered 293
13.2.5.3 Recent developments 294
13.2.5.3.1 Deals 294
13.2.6 ACADIA PHARMACEUTICALS INC. 295
13.2.6.1 Business overview 295
13.2.6.2 Products offered 296
13.2.6.3 Recent developments 296
13.2.6.3.1 Product approvals 296
13.2.7 AURINIA PHARMACEUTICALS INC. 297
13.2.7.1 Business overview 297
13.2.7.2 Products offered 298
13.2.7.3 Recent developments 298
13.2.7.3.1 Product approvals 298
13.2.8 MERCK & CO., INC. 300
13.2.8.1 Business overview 300
13.2.8.2 Product pipeline 301
13.2.8.3 Recent developments 302
13.2.8.3.1 Deals 302
13.2.8.3.2 Other developments 302
13.2.9 JOHNSON & JOHNSON SERVICES, INC. 303
13.2.9.1 Business overview 303
13.2.9.2 Product pipeline 304
13.2.9.3 Recent developments 305
13.2.9.3.1 Other developments 305
13.2.10 SWK HOLDINGS 306
13.2.10.1 Business overview 306
13.2.10.2 Product pipeline 307
13.2.10.3 Recent developments 307
13.2.10.3.1 Other developments 307
13.2.11 R-PHARM JSC 308
13.2.11.1 Business overview 308
13.2.11.2 Products in pipeline 308
13.2.12 ENTERA BIO LTD. 309
13.2.12.1 Business overview 309
13.2.12.2 Product pipeline 309
13.2.12.3 Recent developments 310
13.2.12.3.1 Deals 310
13.2.12.3.2 Other developments 310
?
13.2.13 PROXIMA CONCEPTS 311
13.2.13.1 Business overview 311
13.2.13.2 Products in pipeline 311
13.3 OTHER PLAYERS 312
13.3.1 ASTRAZENECA PLC 312
13.3.2 REGOR THERAPEUTICS GROUP 312
13.3.3 TERNS PHARMACEUTICALS, INC. 313
13.3.4 STRUCTURE THERAPEUTICS 313
13.3.5 VIKING THERAPEUTICS 314
13.3.6 PROTAGONIST THERAPEUTICS INC. 314
13.3.7 RANI THERAPEUTICS 315
13.3.8 CARMOT THERAPEUTICS, INC. 315
13.3.9 ZEALAND PHARMA 316
13.3.10 SCIWIND BIOSCIENCES CO., LTD. 316
13.3.11 JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. 317
14 APPENDIX 318
14.1 DISCUSSION GUIDE 318
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL 322
14.3 CUSTOMIZATION OPTIONS 324
14.4 RELATED REPORTS 324
14.5 AUTHOR DETAILS 325
TABLE 1 ORAL PROTEINS & PEPTIDES MARKET: IMPACT ANALYSIS 54
TABLE 2 ORAL PROTEINS & PEPTIDES MARKET: ROLE OF RAW MATERIAL VENDORS 60
TABLE 3 ORAL PROTEINS & PEPTIDES MARKET: ROLE OF PRODUCT PROVIDERS 60
TABLE 4 ORAL PROTEINS & PEPTIDES MARKET: ROLE OF END USERS 60
TABLE 5 ORAL PROTEINS & PEPTIDES MARKET: ROLE OF REGULATORY AUTHORITIES 61
TABLE 6 ORAL PROTEINS & PEPTIDES MARKET: PORTER'S FIVE FORCES ANALYSIS 64
TABLE 7 BUYING CRITERIA FOR ORAL PROTEINS & PEPTIDES, BY END USER 68
TABLE 8 AVERAGE SELLING PRICE OF ORAL PROTEIN & PEPTIDE PRODUCTS,
BY KEY PLAYER, 2024 (USD) 69
TABLE 9 AVERAGE SELLING PRICE OF ORAL PROTEIN & PEPTIDE PRODUCTS,
BY COUNTRY AND REGION, 2024 (USD) 70
TABLE 10 REGULATORY SCENARIO FOR ORAL PROTEINS & PEPTIDES MARKET 71
TABLE 11 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 72
TABLE 12 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 72
TABLE 13 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 73
TABLE 14 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 74
TABLE 15 ORAL PEPTIDES IN CLINICAL PIPELINE (AS OF JANUARY 2025) 78
TABLE 16 PATENTS FILED, 2014-2025 79
TABLE 17 INNOVATIONS AND PATENT REGISTRATIONS, 2023-2024 81
TABLE 18 ORAL PROTEINS & PEPTIDES MARKET: DETAILED LIST OF
CONFERENCES & EVENTS 82
TABLE 19 US ADJUSTED RECIPROCAL TARIFF RATES 86
TABLE 20 ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2023-2030 (USD MILLION) 91
TABLE 21 SEMAGLUTIDE MARKET, BY REGION, 2023-2030 (USD MILLION) 92
TABLE 22 NORTH AMERICA: SEMAGLUTIDE MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 92
TABLE 23 EUROPE: SEMAGLUTIDE MARKET, BY COUNTRY, 2023-2030 (USD MILLION) 92
TABLE 24 ASIA PACIFIC: SEMAGLUTIDE MARKET, BY COUNTRY, 2023-2030 (USD MILLION) 93
TABLE 25 LATIN AMERICA: SEMAGLUTIDE MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 93
TABLE 26 MIDDLE EAST: SEMAGLUTIDE MARKET, BY REGION, 2023-2030 (USD MILLION) 93
TABLE 27 GCC COUNTRIES: SEMAGLUTIDE MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 94
TABLE 28 CALCITONIN MARKET, BY REGION, 2023-2030 (USD MILLION) 94
TABLE 29 NORTH AMERICA: CALCITONIN MARKET, BY COUNTRY, 2023-2030 (USD MILLION) 95
TABLE 30 EUROPE: CALCITONIN MARKET, BY COUNTRY, 2023-2030 (USD MILLION) 95
TABLE 31 ASIA PACIFIC: CALCITONIN MARKET, BY COUNTRY, 2023-2030 (USD MILLION) 95
TABLE 32 LATIN AMERICA: CALCITONIN MARKET, BY COUNTRY, 2023-2030 (USD MILLION) 96
TABLE 33 MIDDLE EAST: CALCITONIN MARKET, BY REGION, 2023-2030 (USD MILLION) 96
TABLE 34 GCC COUNTRIES: CALCITONIN MARKET, BY COUNTRY, 2023-2030 (USD MILLION) 96
TABLE 35 LINACLOTIDE MARKET, BY REGION, 2023-2030 (USD MILLION) 97
TABLE 36 NORTH AMERICA: LINACLOTIDE MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 97
TABLE 37 EUROPE: LINACLOTIDE MARKET, BY COUNTRY, 2023-2030 (USD MILLION) 98
TABLE 38 ASIA PACIFIC: LINACLOTIDE MARKET, BY COUNTRY, 2023-2030 (USD MILLION) 98
TABLE 39 LATIN AMERICA: LINACLOTIDE MARKET, BY COUNTRY, 2023-2030 (USD MILLION) 98
TABLE 40 MIDDLE EAST: LINACLOTIDE MARKET, BY REGION, 2023-2030 (USD MILLION) 99
TABLE 41 GCC COUNTRIES: LINACLOTIDE MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 99
TABLE 42 TROFINETIDE MARKET, BY REGION, 2023-2030 (USD MILLION) 100
TABLE 43 NORTH AMERICA: TROFINETIDE MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 100
TABLE 44 EUROPE: TROFINETIDE MARKET, BY COUNTRY, 2023-2030 (USD MILLION) 100
TABLE 45 ASIA PACIFIC: TROFINETIDE MARKET, BY COUNTRY, 2023-2030 (USD MILLION) 101
TABLE 46 LATIN AMERICA: TROFINETIDE MARKET, BY COUNTRY, 2023-2030 (USD MILLION) 101
TABLE 47 MIDDLE EAST: TROFINETIDE MARKET, BY REGION, 2023-2030 (USD MILLION) 101
TABLE 48 GCC COUNTRIES: TROFINETIDE MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 102
TABLE 49 VOCLOSPORIN MARKET, BY REGION, 2023-2030 (USD MILLION) 102
TABLE 50 NORTH AMERICA: VOCLOSPORIN MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 103
TABLE 51 EUROPE: VOCLOSPORIN MARKET, BY COUNTRY, 2023-2030 (USD MILLION) 103
TABLE 52 ASIA PACIFIC: VOCLOSPORIN MARKET, BY COUNTRY, 2023-2030 (USD MILLION) 103
TABLE 53 LATIN AMERICA: VOCLOSPORIN MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 104
TABLE 54 PLECANATIDE MARKET, BY REGION, 2023-2030 (USD MILLION) 104
TABLE 55 NORTH AMERICA: PLECANATIDE MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 105
TABLE 56 EUROPE: PLECANATIDE MARKET, BY COUNTRY, 2023-2030 (USD MILLION) 105
TABLE 57 ASIA PACIFIC: PLECANATIDE MARKET, BY COUNTRY, 2023-2030 (USD MILLION) 105
TABLE 58 LATIN AMERICA: PLECANATIDE MARKET, BY COUNTRY, 2023-2030 (USD MILLION) 106
TABLE 59 MIDDLE EAST: PLECANATIDE MARKET, BY REGION, 2023-2030 (USD MILLION) 106
TABLE 60 GCC COUNTRIES: PLECANATIDE MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 106
TABLE 61 OTHER ORAL PROTEIN & PEPTIDE MOLECULES MARKET, BY REGION,
2023-2030 (USD MILLION) 107
TABLE 62 NORTH AMERICA: OTHER ORAL PROTEIN & PEPTIDE MOLECULES MARKET,
BY COUNTRY, 2023-2030 (USD MILLION) 107
TABLE 63 EUROPE: OTHER ORAL PROTEIN & PEPTIDE MOLECULES MARKET,
BY COUNTRY, 2023-2030 (USD MILLION) 108
TABLE 64 ASIA PACIFIC: OTHER ORAL PROTEIN & PEPTIDE MOLECULES MARKET,
BY COUNTRY, 2023-2030 (USD MILLION) 108
TABLE 65 LATIN AMERICA: OTHER ORAL PROTEIN & PEPTIDE MOLECULES MARKET,
BY COUNTRY, 2023-2030 (USD MILLION) 109
TABLE 66 MIDDLE EAST: OTHER ORAL PROTEIN & PEPTIDE MOLECULES MARKET,
BY REGION, 2023-2030 (USD MILLION) 109
TABLE 67 GCC COUNTRIES: OTHER ORAL PROTEIN & PEPTIDE MOLECULES MARKET,
BY COUNTRY, 2023-2030 (USD MILLION) 109
TABLE 68 ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS,
2023-2030 (USD MILLION) 111
TABLE 69 GLP-1 RECEPTOR AGONISTS MARKET, BY REGION, 2023-2030 (USD MILLION) 112
TABLE 70 NORTH AMERICA: GLP-1 RECEPTOR AGONISTS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 112
TABLE 71 EUROPE: GLP-1 RECEPTOR AGONISTS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 112
TABLE 72 ASIA PACIFIC: GLP-1 RECEPTOR AGONISTS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 113
TABLE 73 LATIN AMERICA: GLP-1 RECEPTOR AGONISTS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 113
TABLE 74 MIDDLE EAST: GLP-1 RECEPTOR AGONISTS MARKET, BY REGION,
2023-2030 (USD MILLION) 113
TABLE 75 GCC COUNTRIES: GLP-1 RECEPTOR AGONISTS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 114
TABLE 76 CGRP RECEPTOR ANTAGONISTS MARKET, BY REGION, 2023-2030 (USD MILLION) 114
TABLE 77 NORTH AMERICA: CGRP RECEPTOR ANTAGONISTS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 115
TABLE 78 EUROPE: CGRP RECEPTOR ANTAGONISTS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 115
TABLE 79 ASIA PACIFIC: CGRP RECEPTOR ANTAGONISTS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 115
TABLE 80 LATIN AMERICA: CGRP RECEPTOR ANTAGONISTS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 116
TABLE 81 MIDDLE EAST: CGRP RECEPTOR ANTAGONISTS MARKET, BY REGION,
2023-2030 (USD MILLION) 116
TABLE 82 GCC COUNTRIES: CGRP RECEPTOR ANTAGONISTS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 116
TABLE 83 GC-C AGONISTS MARKET, BY REGION, 2023-2030 (USD MILLION) 117
TABLE 84 NORTH AMERICA: GC-C AGONISTS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 117
TABLE 85 EUROPE: GC-C AGONISTS MARKET, BY COUNTRY, 2023-2030 (USD MILLION) 118
TABLE 86 ASIA PACIFIC: GC-C AGONISTS MARKET, BY COUNTRY, 2023-2030 (USD MILLION) 118
TABLE 87 LATIN AMERICA: GC-C AGONISTS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 118
TABLE 88 MIDDLE EAST: GC-C AGONISTS MARKET, BY REGION, 2023-2030 (USD MILLION) 119
TABLE 89 GCC COUNTRIES: GC-C AGONISTS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 119
TABLE 90 GPE MARKET, BY REGION, 2023-2030 (USD MILLION) 120
TABLE 91 NORTH AMERICA: GPE MARKET, BY COUNTRY, 2023-2030 (USD MILLION) 120
TABLE 92 EUROPE: GPE MARKET, BY COUNTRY, 2023-2030 (USD MILLION) 120
TABLE 93 ASIA PACIFIC: GPE MARKET, BY COUNTRY, 2023-2030 (USD MILLION) 121
TABLE 94 LATIN AMERICA: GPE MARKET, BY COUNTRY, 2023-2030 (USD MILLION) 121
TABLE 95 MIDDLE EAST: GPE MARKET, BY REGION, 2023-2030 (USD MILLION) 121
TABLE 96 GCC COUNTRIES: GPE MARKET, BY COUNTRY, 2023-2030 (USD MILLION) 122
TABLE 97 CNI MARKET, BY REGION, 2023-2030 (USD MILLION) 122
TABLE 98 NORTH AMERICA: CNI MARKET, BY COUNTRY, 2023-2030 (USD MILLION) 123
TABLE 99 EUROPE: CNI MARKET, BY COUNTRY, 2023-2030 (USD MILLION) 123
TABLE 100 ASIA PACIFIC: CNI MARKET, BY COUNTRY, 2023-2030 (USD MILLION) 123
TABLE 101 OTHER ORAL PROTEIN & PEPTIDE DRUG CLASSES MARKET, BY REGION,
2023-2030 (USD MILLION) 124
TABLE 102 NORTH AMERICA: OTHER ORAL PROTEIN & PEPTIDE DRUG CLASSES MARKET,
BY COUNTRY, 2023-2030 (USD MILLION) 125
TABLE 103 EUROPE: OTHER ORAL PROTEIN & PEPTIDE DRUG CLASSES MARKET,
BY COUNTRY, 2023-2030 (USD MILLION) 125
TABLE 104 ASIA PACIFIC: OTHER ORAL PROTEIN & PEPTIDE DRUG CLASSES MARKET,
BY COUNTRY, 2023-2030 (USD MILLION) 125
TABLE 105 LATIN AMERICA: OTHER ORAL PROTEIN & PEPTIDE DRUG CLASSES MARKET,
BY COUNTRY, 2023-2030 (USD MILLION) 126
TABLE 106 MIDDLE EAST: OTHER ORAL PROTEIN & PEPTIDE DRUG CLASSES MARKET,
BY REGION, 2023-2030 (USD MILLION) 126
TABLE 107 GCC COUNTRIES: OTHER ORAL PROTEIN & PEPTIDE DRUG CLASSES MARKET,
BY COUNTRY, 2023-2030 (USD MILLION) 126
TABLE 108 ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION,
2023-2030 (USD MILLION) 128
TABLE 109 ORAL PROTEIN & PEPTIDE TABLETS MARKET, BY REGION,
2023-2030 (USD MILLION) 129
TABLE 110 NORTH AMERICA: ORAL PROTEIN & PEPTIDE TABLETS MARKET, BY COUNTRY, 2023-2030 (USD MILLION) 129
TABLE 111 EUROPE: ORAL PROTEIN & PEPTIDE TABLETS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 129
TABLE 112 ASIA PACIFIC: ORAL PROTEIN & PEPTIDE TABLETS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 130
TABLE 113 LATIN AMERICA: ORAL PROTEIN & PEPTIDE TABLETS MARKET, BY COUNTRY, 2023-2030 (USD MILLION) 130
TABLE 114 MIDDLE EAST: ORAL PROTEIN & PEPTIDE TABLETS MARKET, BY REGION,
2023-2030 (USD MILLION) 130
TABLE 115 GCC COUNTRIES: ORAL PROTEIN & PEPTIDE TABLETS MARKET, BY COUNTRY, 2023-2030 (USD MILLION) 131
TABLE 116 ORAL PROTEIN & PEPTIDE CAPSULES MARKET, BY REGION,
2023-2030 (USD MILLION) 131
TABLE 117 NORTH AMERICA: ORAL PROTEIN & PEPTIDE CAPSULES MARKET, BY COUNTRY, 2023-2030 (USD MILLION) 132
TABLE 118 EUROPE: ORAL PROTEIN & PEPTIDE CAPSULES MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 132
TABLE 119 ASIA PACIFIC: ORAL PROTEIN & PEPTIDE CAPSULES MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 132
TABLE 120 LATIN AMERICA: ORAL PROTEIN & PEPTIDE CAPSULES MARKET, BY COUNTRY, 2023-2030 (USD MILLION) 133
TABLE 121 MIDDLE EAST: ORAL PROTEIN & PEPTIDE CAPSULES MARKET, BY REGION,
2023-2030 (USD MILLION) 133
TABLE 122 GCC COUNTRIES: ORAL PROTEIN & PEPTIDE CAPSULES MARKET, BY COUNTRY, 2023-2030 (USD MILLION) 133
TABLE 123 ORAL PROTEIN & PEPTIDE SOLUTIONS MARKET, BY REGION,
2023-2030 (USD MILLION) 134
TABLE 124 NORTH AMERICA: ORAL PROTEIN & PEPTIDE SOLUTIONS MARKET, BY COUNTRY, 2023-2030 (USD MILLION) 134
TABLE 125 EUROPE: ORAL PROTEIN & PEPTIDE SOLUTIONS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 135
TABLE 126 ASIA PACIFIC: ORAL PROTEIN & PEPTIDE SOLUTIONS MARKET, BY COUNTRY, 2023-2030 (USD MILLION) 135
TABLE 127 LATIN AMERICA: ORAL PROTEIN & PEPTIDE SOLUTIONS MARKET, BY COUNTRY, 2023-2030 (USD MILLION) 136
TABLE 128 MIDDLE EAST: ORAL PROTEIN & PEPTIDE SOLUTIONS MARKET, BY REGION,
2023-2030 (USD MILLION) 136
TABLE 129 GCC COUNTRIES: ORAL PROTEIN & PEPTIDE SOLUTIONS MARKET, BY COUNTRY, 2023-2030 (USD MILLION) 136
TABLE 130 ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA,
2023-2030 (USD MILLION) 138
TABLE 131 ORAL PROTEINS & PEPTIDES MARKET FOR DIABETES, BY REGION,
2023-2030 (USD MILLION) 139
TABLE 132 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR DIABETES,
BY COUNTRY, 2023-2030 (USD MILLION) 139
TABLE 133 EUROPE: ORAL PROTEINS & PEPTIDES MARKET FOR DIABETES, BY COUNTRY, 2023-2030 (USD MILLION) 140
TABLE 134 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET FOR DIABETES, BY COUNTRY, 2023-2030 (USD MILLION) 140
TABLE 135 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR DIABETES,
BY COUNTRY, 2023-2030 (USD MILLION) 141
TABLE 136 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET FOR DIABETES, BY REGION, 2023-2030 (USD MILLION) 141
TABLE 137 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET FOR DIABETES,
BY COUNTRY, 2023-2030 (USD MILLION) 141
TABLE 138 ORAL PROTEINS & PEPTIDES MARKET FOR CNS DISORDERS, BY REGION,
2023-2030 (USD MILLION) 142
TABLE 139 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR CNS DISORDERS,
BY COUNTRY, 2023-2030 (USD MILLION) 143
TABLE 140 EUROPE: ORAL PROTEINS & PEPTIDES MARKET FOR CNS DISORDERS,
BY COUNTRY, 2023-2030 (USD MILLION) 143
TABLE 141 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET FOR CNS DISORDERS,
BY COUNTRY, 2023-2030 (USD MILLION) 143
TABLE 142 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR CNS DISORDERS,
BY COUNTRY, 2023-2030 (USD MILLION) 144
TABLE 143 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET FOR CNS DISORDERS,
BY REGION, 2023-2030 (USD MILLION) 144
TABLE 144 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET FOR CNS DISORDERS,
BY COUNTRY, 2023-2030 (USD MILLION) 144
TABLE 145 ORAL PROTEINS & PEPTIDES MARKET FOR GASTROENTEROLOGY, BY REGION, 2023-2030 (USD MILLION) 145
TABLE 146 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR GASTROENTEROLOGY, BY COUNTRY, 2023-2030 (USD MILLION) 146
TABLE 147 EUROPE: ORAL PROTEINS & PEPTIDES MARKET FOR GASTROENTEROLOGY,
BY COUNTRY, 2023-2030 (USD MILLION) 146
TABLE 148 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET FOR GASTROENTEROLOGY,
BY COUNTRY, 2023-2030 (USD MILLION) 146
TABLE 149 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR GASTROENTEROLOGY, BY COUNTRY, 2023-2030 (USD MILLION) 147
TABLE 150 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET FOR GASTROENTEROLOGY, BY REGION, 2023-2030 (USD MILLION) 147
TABLE 151 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET FOR GASTROENTEROLOGY, BY COUNTRY, 2023-2030 (USD MILLION) 147
TABLE 152 ORAL PROTEINS & PEPTIDES MARKET FOR GENETIC DISORDERS, BY REGION, 2023-2030 (USD MILLION) 148
TABLE 153 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR GENETIC DISORDERS, BY COUNTRY, 2023-2030 (USD MILLION) 149
TABLE 154 EUROPE: ORAL PROTEINS & PEPTIDES MARKET FOR GENETIC DISORDERS,
BY COUNTRY, 2023-2030 (USD MILLION) 149
TABLE 155 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET FOR GENETIC DISORDERS,
BY COUNTRY, 2023-2030 (USD MILLION) 149
TABLE 156 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR GENETIC DISORDERS, BY COUNTRY, 2023-2030 (USD MILLION) 150
TABLE 157 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET FOR GENETIC DISORDERS, BY REGION, 2023-2030 (USD MILLION) 150
TABLE 158 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET FOR GENETIC DISORDERS, BY COUNTRY, 2023-2030 (USD MILLION) 150
TABLE 159 ORAL PROTEINS & PEPTIDES MARKET FOR NEPHROLOGY, BY REGION,
2023-2030 (USD MILLION) 151
TABLE 160 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR NEPHROLOGY,
BY COUNTRY, 2023-2030 (USD MILLION) 152
TABLE 161 EUROPE: ORAL PROTEINS & PEPTIDES MARKET FOR NEPHROLOGY, BY COUNTRY, 2023-2030 (USD MILLION) 152
TABLE 162 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET FOR NEPHROLOGY,
BY COUNTRY, 2023-2030 (USD MILLION) 152
TABLE 163 ORAL PROTEINS & PEPTIDES MARKET FOR OBESITY & OVERWEIGHT, BY REGION, 2023-2030 (USD MILLION) 153
TABLE 164 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR
OBESITY & OVERWEIGHT, BY COUNTRY, 2023-2030 (USD MILLION) 154
TABLE 165 EUROPE: ORAL PROTEINS & PEPTIDES MARKET FOR OBESITY & OVERWEIGHT,
BY COUNTRY, 2023-2030 (USD MILLION) 154
TABLE 166 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET FOR OBESITY & OVERWEIGHT, BY COUNTRY, 2023-2030 (USD MILLION) 154
TABLE 167 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR OBESITY & OVERWEIGHT, BY COUNTRY, 2023-2030 (USD MILLION) 155
TABLE 168 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET FOR OBESITY & OVERWEIGHT, BY REGION, 2023-2030 (USD MILLION) 155
TABLE 169 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET FOR OBESITY & OVERWEIGHT, BY COUNTRY, 2023-2030 (USD MILLION) 155
TABLE 170 ORAL PROTEINS & PEPTIDES MARKET FOR OTHER THERAPEUTIC AREAS,
BY REGION, 2023-2030 (USD MILLION) 156
TABLE 171 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023-2030 (USD MILLION) 157
TABLE 172 EUROPE: ORAL PROTEINS & PEPTIDES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023-2030 (USD MILLION) 157
TABLE 173 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023-2030 (USD MILLION) 157
TABLE 174 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023-2030 (USD MILLION) 158
TABLE 175 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2023-2030 (USD MILLION) 158
TABLE 176 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023-2030 (USD MILLION) 158
TABLE 177 ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2023-2030 (USD MILLION) 160
TABLE 178 ORAL PROTEINS & PEPTIDES MARKET FOR HOME CARE SETTINGS, BY REGION, 2023-2030 (USD MILLION) 161
TABLE 179 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2023-2030 (USD MILLION) 161
TABLE 180 EUROPE: ORAL PROTEINS & PEPTIDES MARKET FOR HOME CARE SETTINGS,
BY COUNTRY, 2023-2030 (USD MILLION) 161
TABLE 181 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2023-2030 (USD MILLION) 162
TABLE 182 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2023-2030 (USD MILLION) 162
TABLE 183 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET FOR HOME CARE SETTINGS, BY REGION, 2023-2030 (USD MILLION) 162
TABLE 184 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2023-2030 (USD MILLION) 163
TABLE 185 ORAL PROTEINS & PEPTIDES MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2023-2030 (USD MILLION) 164
TABLE 186 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023-2030 (USD MILLION) 164
TABLE 187 EUROPE: ORAL PROTEINS & PEPTIDES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023-2030 (USD MILLION) 164
TABLE 188 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023-2030 (USD MILLION) 165
TABLE 189 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023-2030 (USD MILLION) 165
TABLE 190 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2023-2030 (USD MILLION) 165
TABLE 191 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023-2030 (USD MILLION) 166
TABLE 192 ORAL PROTEINS & PEPTIDES MARKET FOR HOSPITALS & SPECIALTY CLINICS,
BY REGION, 2023-2030 (USD MILLION) 167
TABLE 193 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2023-2030 (USD MILLION) 167
TABLE 194 EUROPE: ORAL PROTEINS & PEPTIDES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2023-2030 (USD MILLION) 167
TABLE 195 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2023-2030 (USD MILLION) 168
TABLE 196 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2023-2030 (USD MILLION) 168
TABLE 197 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY REGION, 2023-2030 (USD MILLION) 168
TABLE 198 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2023-2030 (USD MILLION) 169
TABLE 199 ORAL PROTEINS & PEPTIDES MARKET, BY REGION, 2023-2030 (USD MILLION) 171
TABLE 200 NORTH AMERICA: KEY MACROINDICATORS 172
TABLE 201 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 173
TABLE 202 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE,
2023-2030 (USD MILLION) 174
TABLE 203 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS,
2023-2030 (USD MILLION) 174
TABLE 204 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2023-2030 (USD MILLION) 175
TABLE 205 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2023-2030 (USD MILLION) 175
TABLE 206 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY END USER,
2023-2030 (USD MILLION) 175
TABLE 207 US: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE,
2023-2030 (USD MILLION) 176
TABLE 208 US: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS,
2023-2030 (USD MILLION) 176
TABLE 209 US: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA,
2023-2030 (USD MILLION) 177
TABLE 210 US: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION,
2023-2030 (USD MILLION) 177
TABLE 211 US: ORAL PROTEINS & PEPTIDES MARKET, BY END USER,
2023-2030 (USD MILLION) 177
TABLE 212 CANADA: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE,
2023-2030 (USD MILLION) 178
TABLE 213 CANADA: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS,
2023-2030 (USD MILLION) 179
TABLE 214 CANADA: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA,
2023-2030 (USD MILLION) 179
TABLE 215 CANADA: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION,
2023-2030 (USD MILLION) 180
TABLE 216 CANADA: ORAL PROTEINS & PEPTIDES MARKET, BY END USER,
2023-2030 (USD MILLION) 180
TABLE 217 EUROPE: KEY MACROINDICATORS 181
TABLE 218 EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 183
TABLE 219 EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE,
2023-2030 (USD MILLION) 183
TABLE 220 EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS,
2023-2030 (USD MILLION) 184
TABLE 221 EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA,
2023-2030 (USD MILLION) 184
TABLE 222 EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION,
2023-2030 (USD MILLION) 185
TABLE 223 EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY END USER,
2023-2030 (USD MILLION) 185
TABLE 224 GERMANY: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE,
2023-2030 (USD MILLION) 186
TABLE 225 GERMANY: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS,
2023-2030 (USD MILLION) 186
TABLE 226 GERMANY: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA,
2023-2030 (USD MILLION) 187
TABLE 227 GERMANY: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION,
2023-2030 (USD MILLION) 187
TABLE 228 GERMANY: ORAL PROTEINS & PEPTIDES MARKET, BY END USER,
2023-2030 (USD MILLION) 187
TABLE 229 UK: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE,
2023-2030 (USD MILLION) 188
TABLE 230 UK: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS,
2023-2030 (USD MILLION) 189
TABLE 231 UK: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA,
2023-2030 (USD MILLION) 189
TABLE 232 UK: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION,
2023-2030 (USD MILLION) 190
TABLE 233 UK: ORAL PROTEINS & PEPTIDES MARKET, BY END USER,
2023-2030 (USD MILLION) 190
TABLE 234 FRANCE: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE,
2023-2030 (USD MILLION) 191
TABLE 235 FRANCE: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS,
2023-2030 (USD MILLION) 191
TABLE 236 FRANCE: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA,
2023-2030 (USD MILLION) 192
TABLE 237 FRANCE: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION,
2023-2030 (USD MILLION) 192
TABLE 238 FRANCE: ORAL PROTEINS & PEPTIDES MARKET, BY END USER,
2023-2030 (USD MILLION) 192
TABLE 239 ITALY: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE,
2023-2030 (USD MILLION) 193
TABLE 240 ITALY: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS,
2023-2030 (USD MILLION) 194
TABLE 241 ITALY: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA,
2023-2030 (USD MILLION) 194
TABLE 242 ITALY: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION,
2023-2030 (USD MILLION) 195
TABLE 243 ITALY: ORAL PROTEINS & PEPTIDES MARKET, BY END USER,
2023-2030 (USD MILLION) 195
TABLE 244 SPAIN: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE,
2023-2030 (USD MILLION) 196
TABLE 245 SPAIN: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS,
2023-2030 (USD MILLION) 196
TABLE 246 SPAIN: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA,
2023-2030 (USD MILLION) 197
TABLE 247 SPAIN: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION,
2023-2030 (USD MILLION) 197
TABLE 248 SPAIN: ORAL PROTEINS & PEPTIDES MARKET, BY END USER,
2023-2030 (USD MILLION) 197
TABLE 249 NETHERLANDS: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE,
2023-2030 (USD MILLION) 198
TABLE 250 NETHERLANDS: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS,
2023-2030 (USD MILLION) 198
TABLE 251 NETHERLANDS: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2023-2030 (USD MILLION) 199
TABLE 252 NETHERLANDS: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION,
2023-2030 (USD MILLION) 199
TABLE 253 NETHERLANDS: ORAL PROTEINS & PEPTIDES MARKET, BY END USER,
2023-2030 (USD MILLION) 199
TABLE 254 REST OF EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE,
2023-2030 (USD MILLION) 200
TABLE 255 REST OF EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS,
2023-2030 (USD MILLION) 201
TABLE 256 REST OF EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2023-2030 (USD MILLION) 201
TABLE 257 REST OF EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2023-2030 (USD MILLION) 202
TABLE 258 REST OF EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY END USER,
2023-2030 (USD MILLION) 202
TABLE 259 ASIA PACIFIC: KEY MACROINDICATORS 204
TABLE 260 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 204
TABLE 261 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE,
2023-2030 (USD MILLION) 205
TABLE 262 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS,
2023-2030 (USD MILLION) 205
TABLE 263 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2023-2030 (USD MILLION) 206
TABLE 264 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION,
2023-2030 (USD MILLION) 206
TABLE 265 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET, BY END USER,
2023-2030 (USD MILLION) 206
TABLE 266 CHINA: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE,
2023-2030 (USD MILLION) 207
TABLE 267 CHINA: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS,
2023-2030 (USD MILLION) 208
TABLE 268 CHINA: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA,
2023-2030 (USD MILLION) 208
TABLE 269 CHINA: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION,
2023-2030 (USD MILLION) 209
TABLE 270 CHINA: ORAL PROTEINS & PEPTIDES MARKET, BY END USER,
2023-2030 (USD MILLION) 209
TABLE 271 JAPAN: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE,
2023-2030 (USD MILLION) 210
TABLE 272 JAPAN: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS,
2023-2030 (USD MILLION) 210
TABLE 273 JAPAN: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA,
2023-2030 (USD MILLION) 211
TABLE 274 JAPAN: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION,
2023-2030 (USD MILLION) 211
TABLE 275 JAPAN: ORAL PROTEINS & PEPTIDES MARKET, BY END USER,
2023-2030 (USD MILLION) 211
TABLE 276 INDIA: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE,
2023-2030 (USD MILLION) 212
TABLE 277 INDIA: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS,
2023-2030 (USD MILLION) 213
TABLE 278 INDIA: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA,
2023-2030 (USD MILLION) 213
TABLE 279 INDIA: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION,
2023-2030 (USD MILLION) 214
TABLE 280 INDIA: ORAL PROTEINS & PEPTIDES MARKET, BY END USER,
2023-2030 (USD MILLION) 214
TABLE 281 AUSTRALIA: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE,
2023-2030 (USD MILLION) 215
TABLE 282 AUSTRALIA: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS,
2023-2030 (USD MILLION) 215
TABLE 283 AUSTRALIA: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA,
2023-2030 (USD MILLION) 216
TABLE 284 AUSTRALIA: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION,
2023-2030 (USD MILLION) 216
TABLE 285 AUSTRALIA: ORAL PROTEINS & PEPTIDES MARKET, BY END USER,
2023-2030 (USD MILLION) 216
TABLE 286 SOUTH KOREA: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE,
2023-2030 (USD MILLION) 217
TABLE 287 SOUTH KOREA: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS,
2023-2030 (USD MILLION) 218
TABLE 288 SOUTH KOREA: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2023-2030 (USD MILLION) 218
TABLE 289 SOUTH KOREA: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION,
2023-2030 (USD MILLION) 219
TABLE 290 SOUTH KOREA: ORAL PROTEINS & PEPTIDES MARKET, BY END USER,
2023-2030 (USD MILLION) 219
TABLE 291 REST OF ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2023-2030 (USD MILLION) 220
TABLE 292 REST OF ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2023-2030 (USD MILLION) 220
TABLE 293 REST OF ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2023-2030 (USD MILLION) 221
TABLE 294 REST OF ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2023-2030 (USD MILLION) 221
TABLE 295 REST OF ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET,
BY END USER, 2023-2030 (USD MILLION) 221
TABLE 296 LATIN AMERICA: KEY MACROINDICATORS 222
TABLE 297 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 223
TABLE 298 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE,
2023-2030 (USD MILLION) 223
TABLE 299 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS,
2023-2030 (USD MILLION) 224
TABLE 300 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2023-2030 (USD MILLION) 224
TABLE 301 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION,
2023-2030 (USD MILLION) 225
TABLE 302 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY END USER,
2023-2030 (USD MILLION) 225
TABLE 303 BRAZIL: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE,
2023-2030 (USD MILLION) 226
TABLE 304 BRAZIL: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS,
2023-2030 (USD MILLION) 226
TABLE 305 BRAZIL: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA,
2023-2030 (USD MILLION) 227
TABLE 306 BRAZIL: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION,
2023-2030 (USD MILLION) 227
TABLE 307 BRAZIL: ORAL PROTEINS & PEPTIDES MARKET, BY END USER,
2023-2030 (USD MILLION) 227
TABLE 308 MEXICO: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE,
2023-2030 (USD MILLION) 228
TABLE 309 MEXICO: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS,
2023-2030 (USD MILLION) 229
TABLE 310 MEXICO: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA,
2023-2030 (USD MILLION) 229
TABLE 311 MEXICO: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION,
2023-2030 (USD MILLION) 230
TABLE 312 MEXICO: ORAL PROTEINS & PEPTIDES MARKET, BY END USER,
2023-2030 (USD MILLION) 230
TABLE 313 REST OF LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2023-2030 (USD MILLION) 231
TABLE 314 REST OF LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2023-2030 (USD MILLION) 231
TABLE 315 REST OF LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2023-2030 (USD MILLION) 232
TABLE 316 REST OF LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET,
BY FORMULATION, 2023-2030 (USD MILLION) 232
TABLE 317 REST OF LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET,
BY END USER, 2023-2030 (USD MILLION) 232
TABLE 318 MIDDLE EAST: KEY MACROINDICATORS 233
TABLE 319 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET, BY REGION,
2023-2030 (USD MILLION) 234
TABLE 320 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE,
2023-2030 (USD MILLION) 234
TABLE 321 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS,
2023-2030 (USD MILLION) 235
TABLE 322 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2023-2030 (USD MILLION) 235
TABLE 323 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION,
2023-2030 (USD MILLION) 236
TABLE 324 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET, BY END USER,
2023-2030 (USD MILLION) 236
TABLE 325 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 236
TABLE 326 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE,
2023-2030 (USD MILLION) 237
TABLE 327 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS,
2023-2030 (USD MILLION) 237
TABLE 328 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2023-2030 (USD MILLION) 238
TABLE 329 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION,
2023-2030 (USD MILLION) 238
TABLE 330 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET, BY END USER,
2023-2030 (USD MILLION) 238
TABLE 331 SAUDI ARABIA: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE,
2023-2030 (USD MILLION) 239
TABLE 332 SAUDI ARABIA: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS,
2023-2030 (USD MILLION) 240
TABLE 333 SAUDI ARABIA: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2023-2030 (USD MILLION) 240
TABLE 334 SAUDI ARABIA: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION,
2023-2030 (USD MILLION) 241
TABLE 335 SAUDI ARABIA: ORAL PROTEINS & PEPTIDES MARKET, BY END USER,
2023-2030 (USD MILLION) 241
TABLE 336 UAE: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE,
2023-2030 (USD MILLION) 242
TABLE 337 UAE: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS,
2023-2030 (USD MILLION) 242
TABLE 338 UAE: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA,
2023-2030 (USD MILLION) 243
TABLE 339 UAE: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION,
2023-2030 (USD MILLION) 243
TABLE 340 UAE: ORAL PROTEINS & PEPTIDES MARKET, BY END USER,
2023-2030 (USD MILLION) 243
TABLE 341 REST OF GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2023-2030 (USD MILLION) 244
TABLE 342 REST OF GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2023-2030 (USD MILLION) 244
TABLE 343 REST OF GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET,
BY THERAPEUTIC AREA, 2023-2030 (USD MILLION) 245
TABLE 344 REST OF GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET,
BY FORMULATION, 2023-2030 (USD MILLION) 245
TABLE 345 REST OF GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2023-2030 (USD MILLION) 245
TABLE 346 REST OF MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2023-2030 (USD MILLION) 246
TABLE 347 REST OF MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2023-2030 (USD MILLION) 246
TABLE 348 REST OF MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2023-2030 (USD MILLION) 247
TABLE 349 REST OF MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2023-2030 (USD MILLION) 247
TABLE 350 REST OF MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET,
BY END USER, 2023-2030 (USD MILLION) 247
TABLE 351 AFRICA: KEY MACROINDICATORS 249
TABLE 352 AFRICA: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE,
2023-2030 (USD MILLION) 249
TABLE 353 AFRICA: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS,
2023-2030 (USD MILLION) 250
TABLE 354 AFRICA: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA,
2023-2030 (USD MILLION) 250
TABLE 355 AFRICA: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION,
2023-2030 (USD MILLION) 251
TABLE 356 AFRICA: ORAL PROTEINS & PEPTIDES MARKET, BY END USER,
2023-2030 (USD MILLION) 251
TABLE 357 OVERVIEW OF STRATEGIES DEPLOYED BY KEY ORAL PROTEIN &
PEPTIDE MANUFACTURERS 252
TABLE 358 ORAL PROTEINS & PEPTIDES MARKET: DEGREE OF COMPETITION 255
TABLE 359 ORAL PROTEINS & PEPTIDES MARKET: REGION FOOTPRINT (KEY PLAYERS) 262
TABLE 360 ORAL PROTEINS & PEPTIDES MARKET: REGION FOOTPRINT (PLAYERS WITH PRODUCTS IN PIPELINE) 262
TABLE 361 ORAL PROTEINS & PEPTIDES MARKET: MOLECULE FOOTPRINT (KEY PLAYERS) 263
TABLE 362 ORAL PROTEINS & PEPTIDES MARKET: FORMULATION FOOTPRINT (KEY PLAYERS) 264
TABLE 363 ORAL PROTEINS & PEPTIDES MARKET: THERAPEUTIC AREA
FOOTPRINT (KEY PLAYERS) 264
TABLE 364 ORAL PROTEINS & PEPTIDES MARKET: THERAPEUTIC AREA FOOTPRINT (PLAYERS WITH PRODUCTS IN PIPELINE) 265
TABLE 365 ORAL PROTEINS & PEPTIDES MARKET: DETAILED LIST OF KEY STARTUPS/SMES 268
TABLE 366 ORAL PROTEINS & PEPTIDES MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES 269
TABLE 367 ORAL PROTEINS & PEPTIDES MARKET: PRODUCT APPROVALS,
JANUARY 2021-JANUARY 2025 271
TABLE 368 ORAL PROTEINS & PEPTIDES MARKET: DEALS, JANUARY 2021-JANUARY 2025 273
TABLE 369 ORAL PROTEINS & PEPTIDES MARKET: EXPANSIONS,
JANUARY 2021- JANUARY 2025 274
TABLE 370 ORAL PROTEINS & PEPTIDES MARKET: OTHER DEVELOPMENTS,
JANUARY 2021- JANUARY 2025 275
TABLE 371 NOVO NORDISK A/S: COMPANY OVERVIEW 276
TABLE 372 NOVO NORDISK A/S: PRODUCTS OFFERED 277
TABLE 373 NOVO NORDISK A/S: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2021-MARCH 2025 278
TABLE 374 NOVO NORDISK A/S: DEALS, JANUARY 2021-MARCH 2025 278
TABLE 375 NOVO NORDISK: EXPANSIONS, JANUARY 2021-MARCH 2025 279
TABLE 376 NOVO NORDISK: OTHER DEVELOPMENTS, JANUARY 2021-MARCH 2025 280
TABLE 377 ABBVIE INC.: COMPANY OVERVIEW 281
TABLE 378 ABBVIE INC.: PRODUCTS OFFERED 282
TABLE 379 ABBVIE INC.: PRODUCT APPROVALS, JANUARY 2021-JANUARY 2025 283
TABLE 380 ABBVIE INC.: DEALS, JANUARY 2021-JANUARY 2025 283
TABLE 381 PFIZER INC.: COMPANY OVERVIEW 285
TABLE 382 PFIZER INC.: PRODUCT PIPELINE 286
TABLE 383 PFIZER INC.: PRODUCT APPROVALS, JANUARY 2021-MARCH 2025 287
TABLE 384 PFIZER INC.: DEALS, JANUARY 2021-MARCH 2025 287
TABLE 385 PFIZER INC.: OTHER DEVELOPMENTS, JANUARY 2021-MARCH 2025 287
TABLE 386 BAUSCH HEALTH COMPANIES: COMPANY OVERVIEW 289
TABLE 387 BAUSCH HEALTH COMPANIES: PRODUCTS OFFERED 290
TABLE 388 BAUSCH HEALTH COMPANIES: PRODUCT APPROVALS,
JANUARY 2021-JANUARY 2025 291
TABLE 389 CHIESI FARMACEUTICI S.P.A.: COMPANY OVERVIEW 292
TABLE 390 CHIESI FARMACEUTICI S.P.A.: PRODUCTS OFFERED 293
TABLE 391 CHIESI FARMACEUTICI S.P.A.: DEALS, JANUARY 2021-JANUARY 2025 294
TABLE 392 ACADIA PHARMACEUTICALS INC.: COMPANY OVERVIEW 295
TABLE 393 ACADIA PHARMACEUTICALS INC.: PRODUCTS OFFERED 296
TABLE 394 ACADIA PHARMACEUTICALS INC.: PRODUCT APPROVALS,
JANUARY 2021-JANUARY 2025 296
TABLE 395 AURINIA PHARMACEUTICALS INC.: COMPANY OVERVIEW 297
TABLE 396 AURINIA PHARMACEUTICALS INC.: PRODUCTS OFFERED 298
TABLE 397 AURINIA PHARMACEUTICALS INC.: PRODUCT APPROVALS, JANUARY 2021-JANUARY 2025 298
TABLE 398 MERCK & CO., INC.: COMPANY OVERVIEW 300
TABLE 399 MERCK & CO., INC.: PRODUCT PIPELINE 301
TABLE 400 MERCK & CO., INC.: DEALS, JANUARY 2021-JANUARY 2025 302
TABLE 401 MERCK & CO., INC.: OTHER DEVELOPMENTS, JANUARY 2021-JANUARY 2025 302
TABLE 402 JOHNSON & JOHNSON SERVICES, INC.: COMPANY OVERVIEW 303
TABLE 403 JOHNSON & JOHNSON SERVICES, INC.: PRODUCT PIPELINE 304
TABLE 404 JOHNSON & JOHNSON SERVICES, INC.: OTHER DEVELOPMENTS,
JANUARY 2021-MARCH 2025 305
TABLE 405 SWK HOLDINGS: COMPANY OVERVIEW 306
TABLE 406 SWK HOLDINGS: PRODUCT PIPELINE 307
TABLE 407 SWK HOLDINGS: OTHER DEVELOPMENTS, JANUARY 2021-JANUARY 2025 307
TABLE 408 R-PHARM JSC: COMPANY OVERVIEW 308
TABLE 409 R-PHARM JSC: PRODUCTS IN PIPELINE 308
TABLE 410 ENTERA BIO: COMPANY OVERVIEW 309
TABLE 411 ENTERA BIO: PRODUCT PIPELINE 309
TABLE 412 ENTERA BIO: DEALS, JANUARY 2021-JANUARY 2025 310
TABLE 413 ENTERA BIO: OTHER DEVELOPMENTS, JANUARY 2021-JANUARY 2025 310
TABLE 414 PROXIMA CONCEPTS: COMPANY OVERVIEW 311
TABLE 415 PROXIMA CONCEPTS: PRODUCTS IN PIPELINE 311
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security